Preventing Vancomycin-Induced Nephrotoxicity Vancomycin-Induced Nephrotoxicity,Magnesium Supplementation,Acute kidney injury
Conditions
Interventions
Group A (Magnesium group) Vancomycin plus Magnesium supplementation to maintain serum magnesium 2 to 3 mg/dl during therapy (Mg monitored q48h, dose adjusted,Group B (Control): Vancomycin alone (stand
Experimental Drug,No Intervention No treatment
Magnesium group,Control group
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1.Age more18 years 2. Receiving vancomycin 5 consecutive days 3.Baseline serum creatinine more 1.5 mg/dl or eGFR more 60 4.Normal baseline magnesium level
Exclusion criteria
Exclusion criteria: 1.CKD stage 4 5 2.Current magnesium supplementation or magnesium-containing drugs 3.Concomitant nephrotoxic drugs (gamphotericin B cisplatin) 4.Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite outcomes of incidence of Acute Kidney Injury RRT Mortality rate at 7 days after end of the intervention Sereum Creatinine rising | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of Acute Kidney Injury RRT Mortality rate at 7 days after end of the study Sereum Creatinine rising | — |
Countries
Thailand
Contacts
Public ContactSupawiwatch Rodjanasingha
Hua-Hin Hospital
Outcome results
None listed